Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation

References

• Turagam MK, Mirza M, Werner PH, et al. Circulating biomarkers predictive of postoperative atrial fibrillation. DOI:10.1097/CRD.0000000000000059
   Google Scholar
• Vizzardi E, Curnis A, Latini MG, et al. Risk factors for atrial fibrillation recurrence. J Cardiovasc Med. 2014;15(3):235–253.
   Google Scholar
• Chao T-F, Tsao H-M, Lin Y-J, et al. Clinical outcome of catheter ablation in patients with nonparoxysmal atrial fibrillation: results of 3-year follow-up. Circ Arrhythm Electrophysiol. 2012;5(3):514–520.
   PubMed Web of Science ®Google Scholar
• Nielsen JC, Johannessen A, Raatikainen P, et al. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomsed clinical trial. Heart. 2017;103(5):368–376.
   PubMed Web of Science ®Google Scholar
• Padfield GJ, Steinberg C, Swampillai J, et al. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian registry of atrial fibrillation. Heart Rhythm. 2017;14(6):801–807.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac fibrosis in patients with atrial fibrillation: Mechanisms and clinical implications. J Am Coll Cardiol. 2015;66(8):943–959..
   PubMed Web of Science ®Google Scholar
• Masson S, Aleksova A, Favero C, et al. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart. 2010;96(23):1909–1914.
   PubMed Web of Science ®Google Scholar
• Sandler N, Kaczmarek E, Itagaki K, et al. Mitochondrial DAMPs are released during cardiopulmonary bypass surgery and are associated with postoperative atrial fibrillation. Heart Lung Circ. 2018;27(1):122–129.
   PubMed Web of Science ®Google Scholar
• Hu X-R, Wang X-H, Liu H-F, et al. High mobility group box 1 protein: possible pathogenic link to atrial fibrillation. Chin Med J. 2012;125(13):2346–2348. Accessed 2018 Aug 17. Engl. http://www.ncbi.nlm.nih.gov/pubmed/22882860
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang K, Zhao L, et al. Increased serum HMGB1 is related to oxidative stress in patients with atrial fibrillation. J Int Med Res. 2013;41(6):1796–1802.
   PubMed Web of Science ®Google Scholar
• Lancefield TF, Patel SK, Freeman M, et al. The Receptor for Advanced Glycation End products (RAGE) is associated with persistent atrial fibrillation. Oury TD, ed. PLoS One. 2016;11(9):e0161715.
   PubMed Web of Science ®Google Scholar
• Gurses KM, Kocyigit D, Yalcin MU, et al. Platelet Toll-like receptor and its ligand HMGB-1 expression is increased in the left atrium of atrial fibrillation patients. Cytokine. 2018;103:50–56.
   PubMed Web of Science ®Google Scholar
• Gurses KM, Kocyigit D, Yalcin MU, et al. Monocyte toll-like receptor expression in patients with atrial fibrillation. Am J Cardiol. 2016;117(9):1463–1467.
   PubMed Web of Science ®Google Scholar
• Yao C, Veleva T, Scott L, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. May 2018. DOI:10.1161/CIRCULATIONAHA.118.035202
   Web of Science ®Google Scholar
• He G, Tan W, Wang B, et al. Increased M1 macrophages infiltration is associated with thrombogenesis in rheumatic mitral stenosis patients with atrial fibrillation. Lai H-C, ed. PLoS One. 2016;11(3):e0149910.
   PubMed Web of Science ®Google Scholar
• Maan A, Jorgensen NW, Mansour M, et al. Association between heat shock protein-60 and development of atrial fibrillation: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Pacing Clin Electrophysiol. 2016;39(12):1373–1378.
   PubMed Web of Science ®Google Scholar
• Hu Y-F, Yeh H-I, Tsao H-M, et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ Arrhythmia Electrophysiol. 2012;5(2):334–340.
   PubMed Web of Science ®Google Scholar
• Cao H, Xue L, Xu X, et al. Heat shock proteins in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients after mitral valve surgery. Cell Stress Chaperones. 2011;16(5):517–528.
   PubMed Web of Science ®Google Scholar
• Mandal K, Torsney E, Poloniecki J, et al. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann Thorac Surg. 2005;79(3):865–871.
   PubMed Web of Science ®Google Scholar
• Brundel BJJM, Ke L, Dijkhuis A-J, et al. Heat shock proteins as molecular targets for intervention in atrial fibrillation. Cardiovasc Res. 2008;78(3):422–428.
   PubMed Web of Science ®Google Scholar
• Lanters EAH, van Marion DMS, Steen H, et al. The future of atrial fibrillation therapy: intervention on heat shock proteins influencing electropathology is the next in line. Netherlands Heart J. 2015;23(6):327–333.
   PubMed Web of Science ®Google Scholar
• Min TJ, Jo WM, Shin SY, et al. The protective effect of heat shock protein 70 (Hsp70) in atrial fibrillation in various cardiomyopathy conditions. Hear Vessel. 2015;30(3):379–385.
   PubMed Web of Science ®Google Scholar
• Van Marion D, Lanters EA, Wiersma M, et al. Diagnosis and therapy of atrial fibrillation : the past,the present and the future. J Atr Fibrillation. 2015;8(2):1216.
   PubMedGoogle Scholar
• Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156(9):871–881.
   PubMed Web of Science ®Google Scholar
• Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 2000;6(4):435–442.
   PubMed Web of Science ®Google Scholar
• Brundel BJJM, Henning RH, Ke L, et al. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol. 2006;41(3):555–562.
   PubMed Web of Science ®Google Scholar
• Li P, Kurata Y, Maharani N, et al. E3 ligase CHIP and Hsc70 regulate Kv1.5 protein expression and function in mammalian cells. J Mol Cell Cardiol. 2015;86:138–146.
   PubMed Web of Science ®Google Scholar
• Kornej J, Reinhardt C, Kosiuk J, et al. Response of circulating heat shock protein 70 and anti-heat shock protein 70 antibodies to catheter ablation of atrial fibrillation. J Transl Med. 2013;11(1):49.
   PubMedGoogle Scholar
• Rammos K, Koullias GJ, Hassan MO, et al. Low preoperative HSP70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Vascular. 2002;10(3):228–232.
   Google Scholar
• Kim S, Stice J, Chen L, et al. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circulation. 2009;105(12):1186–1195.
   Web of Science ®Google Scholar
• Oc M, Ucar HI, Pinar A, et al. Heat shock protein 60 antibody. A new marker for subsequent atrial fibrillation development. Saudi Med J. 2007;28(6):844–847.
   PubMed Web of Science ®Google Scholar
• Segraves JM, Frishman WH. Highly sensitive cardiac troponin assays. Cardiol Rev. 2015;23(6):1.
   PubMed Web of Science ®Google Scholar
• Reichlin T, Lockwood SJ, Conrad MJ, et al. Early release of high-sensitive cardiac troponin during complex catheter ablation for ventricular tachycardia and atrial fibrillation. J Interv Card Electrophysiol. 2016;47(1):69–74.
   PubMed Web of Science ®Google Scholar
• Aksu T, Golcuk SE, Guler TE, et al. Prediction of mid-term outcome after cryo-balloon ablation of atrial fibrillation using post-procedure high-sensitivity troponin level. Cardiovasc J Afr. 2015;26(4):165–170.
   PubMed Web of Science ®Google Scholar
• Hong CM, Zheng QS, Liu XT, et al. Effects of autoantibodies against M2 muscarinic acetylcholine receptors on rabbit atria in vivo. Cardiology. 2009;112(3):180–187.
   PubMed Web of Science ®Google Scholar
• Yalcin MU, Gurses KM, Kocyigit D, et al. Cardiac autoantibody levels predict recurrence following cryoballoon-based pulmonary vein isolation in paroxysmal atrial fibrillation patients. J Cardiovasc Electrophysiol. 2015;26(6):615–621.
   PubMed Web of Science ®Google Scholar
• Gurses KM, Yalcin MU, Kocyigit D, et al. M2-muscarinic acetylcholine receptor autoantibody levels predict left atrial fibrosis severity in paroxysmal lone atrial fibrillation patients undergoing cryoablation. Europace. 2015;17(2):239–246.
   PubMed Web of Science ®Google Scholar
• Zou C, Zhang Z, Zhao W, et al. Predictive value of pre-procedural autoantibodies against M2-muscarinic acetylcholine receptor for recurrence of atrial fibrillation one year after radiofrequency catheter ablation. J Transl Med. 2013;11(1):7.
   PubMedGoogle Scholar
• Staszewsky L, Masson S, Barlera S, et al. On the behalf of the GISSI-AF investigators. Cardiac remodeling, circulating biomarkers and clinical events in patients with a history of atrial fibrillation. Data from the GISSI-AF Trial. Cardiovasc Drugs Ther. 2015 Dec;29(6):551–561.
   PubMed Web of Science ®Google Scholar
• Hussein AA, Saliba WI, Martin DO, et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation. 2011 May 17;123(19):2077–2082.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen A, Song L, et al. Association between baseline natriuretic peptides and atrial fibrillation recurrence after catheter ablation. Int Heart J. 2016;57(2):183–189.
   PubMed Web of Science ®Google Scholar
• Andrade JG, Khairy P, Macle L, et al. Incidence and significance of early recurrences of atrial fibrillation after cryoballoon ablation: insights from the multicenter Sustained Treatment of Paroxysmal Atrial Fibrillation (STOP AF) trial. Circ Arrhythmia Electrophysiol. 2014;7(1):69–75.
   PubMed Web of Science ®Google Scholar
• Lim HS, Schultz C, Dang J, et al. Time course of inflammation, myocardial injury, and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7(1):83–89.
   PubMed Web of Science ®Google Scholar
• Al-Ani M, Ambadapadi S, Yaron JR, et al. Atrial fibrillation ablation increases inflammation-chemokine modulation suppresses activation of leukocytes isolated after ablation. Cardiovasc Hematol Disord Targets. 2018;17(3):195–204.
   Google Scholar
• Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50(21):2021–2028.
   PubMed Web of Science ®Google Scholar
• Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263–2270.
   PubMed Web of Science ®Google Scholar
• Cabrera-Bueno F, Medina-Palomo C, Ruiz-Salas A, et al. Serum levels of interleukin-2 predict the recurrence of atrial fibrillation after pulmonary vein ablation. Cytokine. 2015;73(1):74–78.
   PubMed Web of Science ®Google Scholar
• Kimura T, Takatsuki S, Inagawa K, et al. Serum inflammation markers predicting successful initial catheter ablation for atrial fibrillation. Heart Lung Circ. 2014;23:636–643.
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang W, Wang C, et al. Associationofpre-ablation levelofpotential blood markers with atrial fibrillation recurrence after catheter ablation: A meta-analysis. Europace. 2017;19(3):392–400.
   PubMed Web of Science ®Google Scholar
• Altun I, Pamukcu B, Yildiz CE, et al. Cardiotrophin-1: A new predictor of atrial fibrillation relapses after successful cardioversion. Bosn J Basic Med Sci. 2015;15(3):68–73.
   PubMed Web of Science ®Google Scholar
• Calabrò P, Limongelli G, Riegler L, et al. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J Mol Cell Cardiol. 2009;46(2):142–148.
   PubMed Web of Science ®Google Scholar
• Wen SN, Liu N, Li SN, et al. Catheter ablation of atrial fibrillation in patients with rheumatoid arthritis. J Cardiol. 2015;66(4):320–325.
   PubMed Web of Science ®Google Scholar
• Sardu C, Santulli G, Santamaria M, et al. Effects of alpha lipoic acid on multiple cytokines and biomarkers and recurrence of atrial fibrillation within 1 year of catheter ablation. Am J Cardiol. 2017;119(9):1382–1386.
   PubMed Web of Science ®Google Scholar
• Sugihara C, Freemantle N, Hughes SG, et al. The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up. cited 2018 May 25. https://link-springer-com.cuhsl.creighton.edu/content/pdf/10.1007%2Fs10840-015-9986-3.pdf.
   Google Scholar
• Kallergis EM, Manios EG, Kanoupakis EM, et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart. 2008;94(2):200–204.
   PubMed Web of Science ®Google Scholar
• Osmancik P, Peroutka Z, Budera P, et al. Changes in cytokine concentrations following successful ablation of atrial fibrillation. Eur Cytokine Netw. 2010;21(4):278–284.
   PubMed Web of Science ®Google Scholar
• Smorodinova N, Bláha M, Melenovský V, et al. Analysis of immune cell populations in atrial myocardium of patients with atrial fibrillation or sinus rhythm. Vinci MC, ed. PLoS One. 2017;12(2):e0172691.
   PubMed Web of Science ®Google Scholar
• Chen M-C, Chang J-P, Liu W-H, et al. Increased inflammatory cell infiltration in the atrial myocardium of patients with atrial fibrillation. Am J Cardiol. 2008;102(7):861–865.
   PubMed Web of Science ®Google Scholar
• Friedrichs K, Adam M, Remane L, et al. Induction of atrial fibrillation by neutrophils critically depends on CD11b/CD18 integrins. Sovari AA, ed. PLoS One. 2014;9(2):e89307.
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96(4):1180–1184.
   PubMed Web of Science ®Google Scholar
• Canpolat U, Aytemir K, Yorgun H, et al. Role of preablation neutrophil/lymphocyte ratio on outcomes of cryoballoon-based atrial fibrillation ablation. Am J Cardiol. 2013;112(4):513–519.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang S, Yan X, et al. Postablation neutrophil/lymphocyte ratio correlates with arrhythmia recurrence after catheter ablation of lone atrial fibrillation. Chin Med J (Engl). 2014;127(6):1033–1038.
   PubMed Web of Science ®Google Scholar
• Li S, Yang F, Jing L, et al. Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation. J Investig Med. 2013;61(4):722–727.
   PubMed Web of Science ®Google Scholar
• Rudolph V, Andrié RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;16(4):470–474.
   PubMed Web of Science ®Google Scholar
• Paschke S, Weidner AF, Paust T, et al. Technical Advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. J Leukoc Biol. 2013;94(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Lennerz C, Barman M, Tantawy M, et al. Colchicine for primary prevention of atrial fibrillation after open-heart surgery: systematic review and meta-analysis. Int J Cardiol. 2017;249:127–137.
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation a randomized controlled study. 2012. DOI:10.1016/j.jacc.2012.07.031
   Google Scholar
• Canpolat U, Aytemir K, Yorgun H, et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace. 2015;17(12):1807–1815.
   PubMed Web of Science ®Google Scholar
• Gunes HM. Relationship between serum osteopontin levels and atrial fibrillation recurrence in patients undergoing cryoballoon catheter ablation. Turk Kardiyol Dern Arsivi-Archives Turkish Soc Cardiol. 2016;45(1):26–32.
   Web of Science ®Google Scholar
• Tian Y, Wang Y, Chen W, et al. Role of serum TGF-β1 level in atrial fibrosis and outcome after catheter ablation for paroxysmal atrial fibrillation. Medicine (Baltimore). 2017;96(51):e9210.
   PubMed Web of Science ®Google Scholar
• Kishima H, Mine T, Takahashi S, et al. The impact of transforming growth factor-β 1 level on outcome after catheter ablation in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2017;28(4):402–409.
   PubMed Web of Science ®Google Scholar
• Wu H, Xie J, Li G, et al. Possible involvement of TGF-β/periostin in fibrosis of right atrial appendages in patients with atrial fibrillation. Int J Clin Exp Pathol. 2015;8(6):6859–6869.
   PubMed Web of Science ®Google Scholar
• Sasaki N, Okumura Y, Watanabe I, et al. Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation. J Interv Card Electrophysiol. 2014;39:241–249.
   PubMed Web of Science ®Google Scholar
• Wu CH, Hu YF, Chou CY, et al. Transforming growth factor-β1level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. Hear Rhythm. 2013;10(1):10–15.
   PubMed Web of Science ®Google Scholar
• Wang W, Liu L, Li Y, et al. Does the expression of transforming growth factor β-1 affect the outcome of the radio frequency modified maze procedure in patients with rheumatic atrial fibrillation? Tex Heart Inst J. 2012;39(1):17–23.
   Google Scholar
• Cao H, Zhou Q, Lan R, et al. A functional polymorphism C-509t in TGF-1 promoter contributes to susceptibility and prognosis of lone atrial fibrillation in chinese population. PLoS One. 2014;9:11.
   Web of Science ®Google Scholar
• Wu H, Xie J, Li G-N, et al. Possible involvement of TGF-β/periostin in fibrosis of right atrial appendages in patients with atrial fibrillation. Int J Clin Exp Pathol. 2015;8(6):6859–6869. Accessed 2018 Apr 13 www.ijcep.com.
   PubMed Web of Science ®Google Scholar
• Verheule S, Sat T, Everett IVT, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ Res. 2004;94(11):1458–1465.
   PubMed Web of Science ®Google Scholar
• Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci. 2008;65(10):1489–1508.
   PubMed Web of Science ®Google Scholar
• Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335–2345.
   PubMedGoogle Scholar
• Midgley AC, Rogers M, Hallett MB, et al. Transforming Growth Factor-␤1 (TGF-␤1)-stimulated fibroblast to myofibroblast differentiation is mediated by Hyaluronan (HA)-facilitated Epidermal Growth Factor Receptor (EGFR) and CD44 co-localization in lipid rafts *. J Biol Chem. 2013. DOI:10.1074/jbc.M113.451336
   PubMed Web of Science ®Google Scholar
• Quan TE, Cowper SE, Bucala R, The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep. 2006;8(2):145–150. Accessed 2018 May 25 http://www.ncbi.nlm.nih.gov/pubmed/16569374.
   PubMedGoogle Scholar
• Liu Y, Niu X-H, Yin X, et al. Elevated circulating fibrocytes is a marker of left atrial fibrosis and recurrence of persistent atrial fibrillation. J Am Heart Assoc. 2018;7(6):e008083.
   PubMed Web of Science ®Google Scholar
• Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90(4):400–405.
   PubMed Web of Science ®Google Scholar
• Goudis CA, Kallergis EM, Vardas PE. Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace. 2012;14(5):623–630.
   PubMed Web of Science ®Google Scholar
• Kallergis EM, Manios EG, Kanoupakis EM, et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation. J Am Coll Cardiol. 2008;52(3):211–215.
   PubMed Web of Science ®Google Scholar
• Swartz MF, Fink GW, Sarwar MF, et al. Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol. 2012;60(18):1799–1806.
   PubMed Web of Science ®Google Scholar
• Marchese P, Bursi F, Delle Donne G, et al. Indexed left atrial volume predicts the recurrence of non-valvular atrial fibrillation after successful cardioversion. Eur J Echocardiogr. 2011;12(3):214–221.
   PubMed Web of Science ®Google Scholar
• Ejima K, Kato K, Arai K, et al. Impact of atrial remodeling on the outcome of radiofrequency catheter ablation of paroxysmal atrial fibrillation. Circ J. 2014;78(4):872–877. Accessed 2018 May 3 http://www.ncbi.nlm.nih.gov/pubmed/24562637.
   PubMed Web of Science ®Google Scholar
• Grubitzsch H, Grabow C, Orawa H, et al. Factors predicting the time until atrial fibrillation recurrence after concomitant left atrial ablation. Eur J Cardio Thoracic Surg. 2008;34(1):67–72.
   PubMed Web of Science ®Google Scholar
• Moon J, Lee H-J, Kim J-Y, et al. Prognostic implications of right and left atrial enlargement after radiofrequency catheter ablation in patients with nonvalvular atrial fibrillation. Korean Circ J. 2015;45(4):301–309.
   PubMed Web of Science ®Google Scholar
• Okumura Y, Watanabe I, Nakai T, et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2011;22(9):987–993.
   PubMed Web of Science ®Google Scholar
• Begg GA, Karim R, Oesterlein T, et al. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. PLoS One. 2018;13:e0189936.
   Web of Science ®Google Scholar
• Boixel C, Fontaine V, Rücker-Martin C, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol. 2003;42(2):336–344.
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Herron AR, Lowry AS, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006;97(4):532–537.
   PubMed Web of Science ®Google Scholar
• Winkle RA, Jarman JW, Mead RH, et al. Predicting atrial fibrillation ablation outcome: the CAAP-AF score. Heart Rhythm. 2016 Nov;13(11):2119–2125.
   PubMed Web of Science ®Google Scholar
• Quan D, Huang H, Kong B, et al. Predictors of late atrial fibrillation recurrence after cryoballoon-based pulmonary vein isolation: a meta-analysis. Kardiol Pol. 2017;75(4):376–385.
   PubMed Web of Science ®Google Scholar
• Hwang HJ, Son JW, Nam BH, et al. Incremental predictive value of pre-procedural N-terminal pro-B-type natriuretic peptide for short-term recurrence in atrial fibrillation ablation. Clin Res Cardiol. 2009 Apr;98(4):213–218.
   PubMed Web of Science ®Google Scholar
• Solheim E, Off MK, Hoff PI, et al. N-terminal pro-B-type natriuretic peptide level at long-term follow-up after atrial fibrillationablation: a marker of reverse atrial remodelling and successful ablation. J Interv Card Electrophysiol. 2012 Aug;34(2):129–136.
   PubMed Web of Science ®Google Scholar
• Hussein AA, Saliba WI, Barakat A, et al. Radiofrequency ablation of persistent atrial fibrillation: diagnosis-to-ablation time, markers of pathways of atrial remodeling, and outcomes. Circ Arrhythm Electrophysiol. 2016 Jan;9(1):e003669.
   PubMed Web of Science ®Google Scholar
• Richter B, Gwechenberger M, Socas A, et al. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. Int J Cardiol. 2011 Oct 20;152(2):231–236.
   PubMed Web of Science ®Google Scholar
• On YK, Jeon ES, Lee SY, et al. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J Thorac Cardiovasc Surg. 2009 Jun;137(6):1515–1520.
   PubMed Web of Science ®Google Scholar
• Gaynor SL, Schuessler RB, Bailey MS, et al. Surgical treatment of atrial fibrillation: predictors of late recurrence. J Thorac Cardiovasc Surg. 2005 Jan;129(1):104–111.
   PubMed Web of Science ®Google Scholar
• Genev IK, Tompkins LA, Khare MM, et al. Comparison of the efficancy and complication rates of the hybrid maze, complete cox-maze and catheter ablation in the treatment of atrial fibrillation. J Atr Fibrillation. 2017 Feb 28;9(5):1543.
   PubMedGoogle Scholar
• Bogachev-Prokophiev A, Zheleznev S, Pivkin A, et al. Assessment of concomitant paroxysmal atrial fibrillation ablation in mitral valve surgery patients based on continuous monitoring: does a different lesion set matter? Interact Cardiovasc Thorac Surg. 2014 Feb;18(2):177–181.
   PubMed Web of Science ®Google Scholar
• Phan K, Xie A, Kumar N, et al. Comparing energy sources for surgical ablation of atrial fibrillation: a Bayesian network meta-analysis of randomized, controlled trials. Eur J Cardiothorac Surg. 2015 Aug;48(2):201–211.
   PubMed Web of Science ®Google Scholar
• Kühne M, Suter Y, Altmann D, et al. Cryoballoon versus radiofrequency catheter ablation of paroxysmal atrial fibrillation: biomarkersof myocardial injury, recurrence rates, and pulmonary vein reconnection patterns. Heart Rhythm. 2010 Dec;7(12):1770–1776.
   PubMed Web of Science ®Google Scholar
• Jeong DS, You JH, Jeon CS, et al. Impact of ablation duration on rhythm outcome after concomitant maze procedure using cryoablation in patients with persistent atrial fibrillation. J Cardiothorac Surg. 2017 Jul 24;12(1):60.
   PubMedGoogle Scholar
• Chang S, Chen Y, Hsu C, et al. Heat shock protein inducer modi fi es arrhythmogenic substrate and inhibits atrial fibrillation in the failing heart. Int J Cardiol. 2013;168(4):4019–4026.
   PubMed Web of Science ®Google Scholar
• Lanters EAH, van Marion DMS, Kik C, et al. HALT & REVERSE: hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation. J Transl Med. 2015;13:347.
   PubMed Web of Science ®Google Scholar
• Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther. 2014;141(3):347–357.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597–605.
   PubMed Web of Science ®Google Scholar
• Bang CN, Greve AM, Abdulla J, et al. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions. Int J Cardiol. 2013;167(3):624–630.
   PubMed Web of Science ®Google Scholar
• Zhang X-D, Gu J, Jiang W-F, et al. Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. Eur Heart J. 2014;35(20):1327–1334.
   PubMed Web of Science ®Google Scholar
• Barekatain A, Razavi M. Antiarrhythmic therapy in atrial fibrillation: indications, guidelines, and safety. Tex Heart Inst J. 2012;39(4):532–534.
   PubMed Web of Science ®Google Scholar
• Singla S, Karam P, Deshmukh AJ, et al. Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation. J Cardiovasc Pharmacol Ther. 2012;17(1):12–20.
   PubMed Web of Science ®Google Scholar
• Xu B, Peng F, Tang W, et al. Short-term antiarrhythmic drugs after catheter ablation for atrial fibrillation: A meta-analysis of randomized controlled trials. Ann Pharmacother. 2016;50(9):697–705.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu H, Ling Z, et al. Efficacy of short-term antiarrhythmic drugs use after catheter ablation of atrial fibrillation-A systematic review with meta-analyses and trial sequential analyses of randomized controlled trials. PLoS One. 2016;11(5):e0156121.
   PubMed Web of Science ®Google Scholar
• Ad N, Holmes SD, Shuman DJ, et al. Amiodarone after surgical ablation for atrial fibrillation: is it really necessary? A prospective randomized controlled trial. J Thorac Cardiovasc Surg. 2016;151(3):798–803.
   PubMed Web of Science ®Google Scholar